 |
|
Effect of Statins on Risk of Coronary Disease
A Meta-analysis of Randomized Controlled Trials
John C. LaRosa, MD;
Jiang He, MD, PhD;
Suma Vupputuri, MPH
JAMA. 1999;282:2340-2346.
ABSTRACT
| |
Context Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women.
Objective To estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women.
Data Sources Trials published in English-language journals were retrieved by searching MEDLINE (1966–December 1998), bibliographies, and authors' reference files.
Study Selection Studies in which participants were randomized to statin or control treatment for at least 4 years and clinical disease or death was the primary outcome were included in the meta-analysis (5 of 182 initially identified).
Data Extraction Information on sample size, study drug duration, type and dosage of statin drug, participant characteristics at baseline, reduction in lipids during intervention, and outcomes was abstracted independently by 2 authors (J.H. and S.V.) using a standardized protocol. Disagreements were resolved by consensus.
Data Synthesis Data from the 5 trials, with 30,817 participants, were included in this meta-analysis. The mean duration of treatment was 5.4 years. Statin drug treatment was associated with a 20% reduction in total cholesterol, 28% reduction in LDL-C, 13% reduction in triglycerides, and 5% increase in high-density lipoprotein cholesterol. Overall, statin drug treatment reduced risk 31% in major coronary events (95% confidence interval [CI], 26%-36%) and 21% in all-cause mortality (95% CI, 14%-28%). The risk reduction in major coronary events was similar between women (29%; 95% CI, 13%-42%) and men (31%; 95% CI, 26%-35%), and between persons aged at least 65 years (32%; 95% CI, 23%-39%) and persons younger than 65 years (31%; 95% CI, 24%-36%).
Conclusions Our meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality. The risk reduction was similar for men and women and for elderly and middle-aged persons.
INTRODUCTION
In a very important sense, the cholesterol "controversy" is no more. A spate of recent clinical trials using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) to lower low-density lipoprotein cholesterol (LDL-C) have demonstrated beyond reasonable doubt that coronary events, both morbid and mortal, can be prevented.1-8 Post hoc analyses of these trials also strongly suggest that stroke rates may be reduced to about the same degree. Observational epidemiology has not identified hypercholesterolemia as a major risk factor for stroke,9 although these data did not distinguish hemorrhage from atherothrombotic stroke.
Most subjects in these studies have been middle-aged men. This led to the suggestion that while elevated LDL-C is a risk factor in women as well as in men and in older as well as in middle-aged individuals, the data from these trials cannot be extrapolated to groups other than middle-aged men. It has been further suggested that, in the absence of such sex- and age-specific data, cholesterol screening is optional except in middle-aged men.10 This has encouraged some insurers, including Medicare, to refuse funding for cholesterol screening in older individuals. While it is difficult to prove, lack of support even for screening may contribute to the rather poor frequency of prescription of cholesterol-lowering regimens even for women with established coronary disease.11
With 1 exception,3 the major statin cholesterol-lowering trials with clinical event end points have included women and those aged 65 years or older. All have reported similar effects in women vs men and in younger vs older subjects. Two trials have issued expanded reports of their findings.2, 5-6
Meta-analysis of these studies can provide a more accurate and precise estimate of subgroup effects than can be derived from individual trials.12 It also provides the opportunity to examine, in the aggregate, the effect of statin-induced cholesterol lowering in men and women across a wide age spectrum.
METHODS
Study Selection
A literature search of the MEDLINE database (1966–December 1998), using the Medical Subject Headings hydroxymethyl-glutaryl-CoA reductase inhibitors, simvastatin, lovastatin, pravastatin, coronary disease, and myocardial infarction as well as the key words statin and coronary heart disease was performed. The search was restricted to studies published in English-language journals, conducted in human subjects, and classified as clinical trials in the MEDLINE database. A manual search was also performed using the authors' reference files and reference lists from original communications and review articles.13-15 The contents of 182 abstracts or full-text manuscripts identified during our literature search were reviewed to determine whether they met the criteria for inclusion. Of these abstracts and manuscripts, 29 statin drug treatment trials were identified. Other publications included reviews, letters to the editor, subgroup analysis, and secondary analysis of data from the 29 published trials.
For inclusion, a study had to meet the following criteria: (1) random allocation of study participants to statin or a placebo control group; (2) no intervention difference, other than use of a statin, between the treatment and control groups; (3) intervention duration of at least 4 years; and (4) clinical disease or death as the primary end point. The mean intervention duration in all outcome trials was more than 4 years. Five trials met these criteria and were included in the meta-analysis.1-8
Major reasons for exclusion of studies were intervention duration of less than 4 years16-36 and trial primary end points that were not clinical events.16-39 Additional reasons for exclusion of studies included comparison of different statin drugs33 and comparison of aggressive or moderate cholesterol lowering with statin drug treatment.39
Data Abstraction
All data were abstracted in duplicate using a standardized protocol and reporting form. Disagreements were resolved by consensus. We did not contact authors to request additional information. Study characteristics recorded were as follows: (1) first author's name, year of publication, and country of origin; (2) number of participants; (3) mean age and age and sex distributions of participants; (4) presence of preexisting myocardial infarction; (5) baseline mean total, LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglyceride levels; (6) net changes in lipids during intervention; (7) type and dosage of statin drug; and (8) intervention duration.
Major coronary events during treatment were abstracted as the primary outcome. They included coronary death, nonfatal myocardial infarction, silent myocardial infarction, or resuscitated cardiac arrest in the Scandinavian Simvastatin Survival Study (4S)1; coronary death or nonfatal myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS),3 the Cholesterol and Recurrent Events Trial (CARE),4-5 and the Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) trial8; and fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).7 In addition, data were abstracted on fatal coronary heart disease, cardiovascular disease deaths, noncardiovascular deaths, and all-cause deaths during treatment.
Statistical Analysis
Both proportional (1 - odds ratio [OR]) and absolute risk reduction were used to measure the effect of statin drug treatment on clinical outcomes. The numbers of various outcomes for both the statin and placebo groups were recorded for each study using 2 x 2 tables. The Peto method was used to calculate pooled ORs of outcomes associated with statin therapy.40 For each trial, the number of individuals in the treatment group in whom an end point of interest was observed (O) was compared with the number that would, if treatment had no effect, have been expected (E) on the basis of the overall experience in the treatment and control groups combined. If treatment was beneficial, then O - E would tend to be negative. The O - E values from each trial were summed and z statistics were used to test whether the total of O - E values differed from 0. Odds ratios were calculated by using [(O - E)/V], where V was the variance of the O - E total.40 To calculate the pooled absolute risk, each study was weighted by its sample size (Nt x Nc)/(Nt + Nc), where Nt and Nc were sample sizes for statin therapy and control groups, respectively. The number needed to treat was calculated by taking the reciprocal of the absolute risk reduction. This represents the number of patients who would have to be treated to prevent 1 outcome event.
A series of prestated subgroup analyses was performed to examine the effect of statin drug treatment on major coronary events. First, the risk reductions of major coronary events and deaths were compared between 2 primary prevention trials3, 7 and 3 secondary prevention trials.1, 4, 8 Furthermore, the risk reductions of major coronary events were calculated by sex and age groups. Four of the 5 trials included participants who were women or aged at least 65 years.1, 4, 7-8 Three of these trials planned subgroup analyses by sex and age group ( 65 years) in their original proposal.1, 4, 8 One trial7 only reported subgroup analysis by median age, which was 57 years for men and 62 years for women.
A sensitivity analysis was conducted to explore the impact of excluding small nonoutcome trials with short intervention duration (<4 years) on risk estimates. Twelve trials that were excluded from the primary analysis and reported at least 1 major coronary event were included in this analysis.16-20,23, 25, 27-30,37
RESULTS
Study Design and Participants
Study design and participant characteristics for the 5 randomized, placebo-controlled, double-blind trials included in our meta-analysis are presented in Table 1. A total of 30,817 participants were included in these trials. Mean follow-up time was 5.4 years and mean age was 59 years. Only men younger than 65 years were included in WOSCOPS, while women and participants who were aged 65 years or older were included in the remaining 4 trials. Three trials (4S, CARE, and LIPID) were conducted in patients with a history of coronary heart disease (secondary prevention trials) and 2 trials (WOSCOPS and AFCAPS/TexCAPS) were conducted in a healthy population (primary prevention trials).
|
|
|
|
Table 1. Characteristics of 5 Randomized Controlled Cholesterol-Lowering Trials Using Statin Drugs*
|
|
|
In 4S, patients with serum total cholesterol levels of 5.5 to 8.0 mmol/L (213-309 mg/dL) and triglyceride levels of 2.5 mmol/L (221 mg/dL) or less while following a lipid-lowering diet were eligible for participation.1 In WOSCOPS, men with serum LDL-C levels of at least 4.0 mmol/L (155 mg/dL) at screening visits (at least 1 LDL-C measurement of 4.5 mmol/L [174 mg/dL] and 1 of  6.0 mmol/L [232 mg/dL]) while following a lipid-lowering diet were eligible for participation.3 In CARE, patients with total serum cholesterol levels of less than 6.2 mmol/L (240 mg/dL), LDL-C levels between 3.0 and 4.5 mmol/L (116-174 mg/dL), and triglyceride levels of less than 4.0 mmol/L (354 mg/dL) were eligible.4 Total cholesterol levels between 4.65 and 6.82 mmol/L (180-264 mg/dL), LDL-C levels between 3.36 and 4.91 mmol/L (130-190 mg/dL), and HDL-C levels of 1.16 mmol/L (45 mg/dL) or less for men and 1.22 mmol/L (47 mg/dL) or less for women were used as entry criteria in AFCAPS/TexCAPS.10 A broad range of serum total cholesterol levels (4.0-7.0 mmol/L [155-271 mg/dL]) and triglyceride levels of less than 5.0 mmol/L (443 mg/dL) were used as entry criteria for LIPID.8 Mean baseline levels of serum lipids in the 5 trials reflected these inclusion criteria.
Effects of Statins on Lipids
The net changes in lipids (percentage change in treatment group - percentage change in placebo group) among those attending follow-up for lipid measurements are shown in Table 1. The mean reduction (weighted by sample size) in total cholesterol, LDL-C, and triglyceride levels was -20%, -28%, and -13%, respectively, and HDL-C was increased by an average of 5% among the 5 trials. The estimates excluded participants who were lost to follow-up before the end of the trial, although those participants were still included in end-point analysis. Assuming that there were few differences in changes in serum lipids between treatment and control groups among dropouts, the differences in lipid changes between treatment and control groups among all participants were likely somewhat smaller than these estimates.
Effects of Lipid Reduction on Coronary Disease and Mortality
Overall, 2042 major coronary events and 748 coronary deaths occurred in participants assigned to placebo and 1490 events and 543 deaths occurred in those allocated to active treatment (Table 2). When the results from the 5 trials were pooled, a significant reduction in the odds of major coronary events and coronary deaths (P<.001 for both) was observed among the participants allocated to active treatment. The reduction in coronary events was 31% (95% confidence interval [CI], 26%-36%) and the reduction in fatal coronary disease was 29% (95% CI, 20%-36%). Compared with control groups, active treatment was associated with an absolute risk reduction in coronary disease of 36 events and 13 deaths per 1000 patients. The number needed to treat was 28 to prevent a major coronary event and 75 to prevent a death from coronary disease.
|
|
|
|
Table 2. Overall Risk Reduction for Major Coronary Events and Deaths From Coronary Disease, Cardiovascular Disease, and All Causes*
|
|
|
Overall, 1297 deaths (868 from cardiovascular disease and 429 from noncardiovascular disease) occurred in control participants and 1046 (646 from cardiovascular disease and 400 from noncardiovascular disease) occurred in those assigned to active treatment (Table 2). Compared with controls, those receiving active treatment had a 21% reduction in the odds of total mortality (95% CI, 14%-28%; P<.001) and a 27% reduction in the odds of cardiovascular mortality (95% CI, 19%-34%; P<.001). Active treatment was also associated with an absolute risk reduction of 16 deaths from all causes and 14 deaths from cardiovascular disease per 1000 patients. The number needed to treat was 61 to prevent a death from all causes and 69 to prevent a death from cardiovascular disease. Noncardiovascular mortality was similar in active treatment and control groups (OR, 0.93; 95% CI, 0.81-1.07; P = .29).
Treatment Effects in Primary and Secondary Prevention Trials
Two primary prevention trials with 13,200 participants and 3 secondary prevention trials with 17,617 participants were included in this meta-analysis. Active treatment was associated with a 34% risk reduction (95% CI, 23%-43%; P<.001) in major coronary events in the 2 primary prevention trials and a 30% risk reduction (95% CI, 24%-35%; P<.001) in the 3 secondary prevention trials. Compared with controls, active treatment was associated with a lower risk of coronary disease mortality (OR, 0.73; 95% CI, 0.51-1.05; P = .09), cardiovascular mortality (OR, 0.68; 95% CI, 0.50-0.93; P = .01), and all-cause mortality (OR, 0.87; 95% CI, 0.71-1.06; P = .18) in the 2 primary prevention trials. Likewise, active treatment was associated with a lower risk of coronary disease mortality (OR, 0.71; 95% CI, 0.63-0.80; P<.001), cardiovascular mortality (OR, 0.73; 95% CI, 0.66-0.82; P<.001), and all-cause mortality (OR, 0.77; 95% CI, 0.70-0.85; P<.001) in the 3 secondary prevention trials. Active treatment was not significantly associated with change in noncardiovascular mortality in the 2 primary prevention trials (OR, 1.04; 95% CI, 0.80-1.35; P = .75) or in the 3 secondary prevention trials (OR, 0.89; 95% CI, 0.75-1.04; P = .15).
Treatment Effects by Sex and Age
Odds ratios of major coronary events associated with statin treatment from individual trials stratified by sex are given in Figure 1, top. In all trials, the odds of coronary events were reduced for those assigned to active treatment compared with controls, and the risk reduction was statistically significant in 2 of 4 trials in women and all 5 trials in men. The overall proportional risk reduction was similar for women (29%; 95% CI, 13%-42%; P<.001) and men (31%; 95% CI, 26%-35%; P<.001) (Table 3). The absolute risk reduction was also similar in women (33 per 1000; 95% CI, 13-52 per 1000) and men (37 per 1000; 95% CI, 29-44 per 1000).
|
|
|
|
Figure. Relative Odds of Major Coronary Events Associated With Statin Treatment From Individual Trials and Overall by Sex and Age
Error bars indicate 95% confidence intervals; see footnote to Table 1 for expansion of study names.
|
|
|
|
|
|
|
Table 3. Overall Risk Reduction for Major Coronary Events by Sex and Age: Results From 5 Randomized Controlled Trials*
|
|
|
In all trials, the odds of coronary events were reduced in active treatment compared with controls stratified by age group (Figure 1, bottom). The risk reduction was statistically significant in all 4 trials among persons aged at least 65 years and in 4 of 5 trials among persons younger than 65 years. The overall proportional risk reduction was similar for persons aged at least 65 years (32%; 95% CI, 23%-39%; P<.001) and persons younger than 65 years (31%; 95% CI, 24%-36%; P<.001) (Table 3). The absolute risk reduction, however, was slightly higher in persons aged at least 65 years (44 per 1000; 95% CI, 30-58 per 1000) compared with persons younger than 65 years (32 per 1000; 95% CI, 24-40 per 1000).
Sensitivity Analysis
After including 12 small nonoutcome trials, estimates for risk reduction were virtually unchanged. Among 17 trials, 19,597 participants were allocated to placebo and 24,601 to active treatment. Of those, 2159 and 1618 developed major coronary events, 776 and 589 died from coronary heart disease, 905 and 697 died from cardiovascular disease, 447 and 410 died from noncardiovascular disease, and 1352 and 1107 died from all causes for the control and active treatment groups, respectively. The corresponding proportional risk reduction was 31% (95% CI, 26%-35%; P<.001) for major coronary events, 28% (95% CI, 19%-35%; P<.001) for fatal coronary disease, 27% (95% CI, 19%-34%; P<.001) for cardiovascular disease mortality, and 22% (95% CI, 15%-28%; P<.001) for all-cause mortality. The mortality from noncardiovascular disease was not significantly different between placebo and treatment groups (OR, 0.91; 95% CI, 0.80-1.04; P = .18).
Safety
Overall, 1021 cancer cases occurred in participants who were allocated to placebo and 1009 in participants who were allocated to active treatment (OR, 0.99; 95% CI, 0.90-1.08; P = .76). Forty study participants had asymptomatic episodes of elevated creatine kinase concentrations (>10 times the upper reference limit) in the control group compared with 50 in the active treatment group (OR, 1.25; 95% CI, 0.83-1.89; P = .29). Two hundred fifty-eight participants had increased aspartate or alanine aminotransferase levels (>3 times the upper reference limit) in the control group compared with 290 in the active treatment group (OR, 1.13; 95% CI, 0.95-1.33; P = .17).
COMMENT
A clear and consistent effect of statin-induced LDL-C lowering in significantly reducing the risk of coronary events, independent of sex or age, has been demonstrated in the individual studies and the meta-analysis presented here. A roughly 30% decline in coronary events is seen in all sex and age groups studied. There are insufficient data from published results (except in CARE and 4S)2, 5-6 to draw any conclusion about sex- or age-specific mortality. Ongoing trials will provide additional information on the effects of LDL-C lowering by statins by sex and age.41-43
It is clear that there is no effect of these interventions on noncardiovascular mortality. Neither those studies whose participants had initially high cholesterol levels (4S, LIPID, and WOSCOPS) nor those whose initial cholesterol levels were lower (CARE and AFCAPS/TexCAPS) reported any increase in noncardiovascular mortality. Because these studies were limited for approximately 5 years, they cannot offer information other than the possible effects of longer exposure to statins or cholesterol lowering. Some of the guidelines and policies that resulted from an unwillingness to extrapolate earlier reported data to women and the elderly should be revisited. Policies designed to limit screening in women and elderly persons10 make no sense and, in fact, are potentially harmful because they diminish in the eyes of both the public and the practicing physician the importance of cholesterol interventions in these groups.
The recent results of the Heart and Estrogen/Progestin Replacement Study (HERS)44 failed to demonstrate benefit on cardiovascular events with a regimen of conjugated equine estrogen and medroxyprogesterone (in dosages of 0.625 and 2.5 mg/d, respectively). At this point, therefore, hormone replacement therapy should not be looked on as an alternative to vigorous interventions to lower LDL-C levels in women, who make up two thirds of the population aged 65 years or older.45
Finally, currently available data do not allow us to draw any conclusions about the effects on total mortality in these sex and age groups beyond those that are already published. It would, however, be wrong to conclude that an effect on morbidity has no implications for the potential effects on mortality. The prevention of a morbid event also prevents that individual from graduating into a much higher risk category for subsequent mortality.
In fact, the benefits of LDL-C lowering on morbidity, particularly in older age groups, have been underappreciated. Prevention of morbid events results in lower prevalence of congestive heart failure, angina, significant arrhythmia, and debilitating strokes. Such interventions are likely to have a beneficial effect on both the quality of life for the individual patients and the cost of caring for older subjects imposed on families and society. By placing undue attention on mortality alone as a measure of the success or failure of an intervention, clinicians fail to account for the importance of avoiding such disabilities. It is irrational to deny the demonstrable benefits of LDL-C lowering by sex and age while we await more definitive information about mortality, particularly given the lack of evidence that statin-induced LDL-C lowering in any way increases noncardiovascular morbidity or mortality.15
In summary, the benefits of LDL-C lowering induced by statins appear to be universal, not defined by sex or age. It is important now to work to extend these benefits to all who are at risk for atherosclerotic cardiovascular disease.
AUTHOR INFORMATION
Financial Disclosure: Dr LaRosa is chairman of the steering committee of the Treating to New Targets Study, a Parke-Davis/Pfizer study of atorvastatin-induced cholesterol lowering in patients with coronary artery disease; he has also received occasional honoraria for speaking or consulting from Bristol-Myers Squibb, Merck & Co, Novartis, and Bayer.
Funding/Support: The authors received no funding for this meta-analysis.
Corresponding Author and Reprints: John C. LaRosa, MD, State University of New York Health Science Center at Brooklyn, 450 Clarkson Ave, Box 01, Brooklyn, NY 11203 (e-mail: jclarosa{at}netmail.hscbklyn.edu).
Author Affiliations: Office of the President, State University of New York Health Science Center at Brooklyn, Brooklyn, NY (Dr LaRosa); and the Department of Epidemiology, Tulane University Medical Center, New Orleans, La (Dr He and Mr Vupputuri).
REFERENCES
| |
1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344:1383-1389.
FULL TEXT
|
ISI
| PUBMED
2. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997;96:4211-4218.
FREE FULL TEXT
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
FREE FULL TEXT
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
FREE FULL TEXT
5. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction. J Am Coll Cardiol. 1998;32:140-146.
FREE FULL TEXT
6. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med. 1998;129:681-689.
FREE FULL TEXT
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
FREE FULL TEXT
8. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
FREE FULL TEXT
9. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke. Lancet. 1995;346:1647-1653.
FULL TEXT
|
ISI
| PUBMED
10. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease. Ann Intern Med. 1996;124:515-517.
FREE FULL TEXT
11. Schrott HG, Bittner V, Vittinghott E, et al. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. JAMA. 1997;277:1281-1286.
FREE FULL TEXT
12. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93-98.
FREE FULL TEXT
13. Cholesterol Treatment Trialists' Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol. 1995;75:1130-1134.
FULL TEXT
|
ISI
| PUBMED
14. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313-321.
FREE FULL TEXT
15. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Circulation. 1998;97:946-952.
FREE FULL TEXT
16. Sahni R, Maniet AR, Gerardo V, Banks VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J. 1991;121:1600-1608.
FULL TEXT
|
ISI
| PUBMED
17. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I. Arch Intern Med. 1991;151:43-49.
FREE FULL TEXT
18. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med. 1993;119:969-976.
FREE FULL TEXT
19. Jones PH, Farmer JA, Cressman MD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia. Clin Cardiol. 1991;14:146-151.
ISI
| PUBMED
20. The Pravastatin Multinational Study Group for Cardiac Risk Factors. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
FULL TEXT
|
ISI
| PUBMED
21. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med. 1994;96:509-515.
FULL TEXT
|
ISI
| PUBMED
22. LaRosa JC, Applegate W, Crouse III JR, et al. Cholesterol lowering in the elderly. Arch Intern Med. 1994;154:529-539.
FREE FULL TEXT
23. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
FREE FULL TEXT
24. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study. Eur Heart J. 1994;15:255-269.
FREE FULL TEXT
25. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary arteriography. Circulation. 1994;89:959-968.
FREE FULL TEXT
26. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-1337.
FREE FULL TEXT
27. Jukema JW, Bruschke AVG, van Boven ADJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 1995;91:2528-2540.
FREE FULL TEXT
28. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). J Am Coll Cardiol. 1995;26:1133-1139.
ABSTRACT
29. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
FULL TEXT
|
ISI
| PUBMED
30. Salonen R, Nyyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). Circulation. 1995;92:1758-1764.
FREE FULL TEXT
31. Lindholm LH, Ekbom T, Dash C, Isaacsson A, Schersten B. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies. J Intern Med. 1996;240:13-22.
FULL TEXT
|
ISI
| PUBMED
32. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population. Am J Med. 1996;101:627-634.
FULL TEXT
|
ISI
| PUBMED
33. Davidson M, McKenny J, Stein E, et al. Comparison on one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.
FULL TEXT
|
ISI
| PUBMED
34. Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Am J Cardiol. 1997;79:893-896.
FULL TEXT
|
ISI
| PUBMED
35. Bertrand ME, McFadden EP, Fruchart JC, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol. 1997;30:863-869.
ABSTRACT
36. Bestehorn HP, Rensing UFE, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. Eur Heart J. 1997;18:226-234.
FREE FULL TEXT
37. MAAS Investigators. Effect of simvastatin on coronary atheroma. Lancet. 1994;344:633-638.
FULL TEXT
|
ISI
| PUBMED
38. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann Intern Med. 1996;124:548-556.
FREE FULL TEXT
39. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
FREE FULL TEXT
40. Fleiss JL. Measures of effect size for categorical data. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:245-260.
41. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment of Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
FULL TEXT
|
ISI
| PUBMED
42. LaRosa JC. Unresolved Issues: Unanswered Questions: Proceedings From the Amstel Hotel Satellite Symposium: Controversies in the Determination of Cardiovascular Therapy. XXth Congress of the European Society of Cardiology; August 22-26, 1998; Vienna, Austria. In press.
43. Gaw A, Blauw GJ, Shepherd J, Murphy M. The PROSPER design: a prospective study of pravastatin in the elderly at risk. Paper presented at: International Congress on Vascular Prevention; May 5-8, 1998; Glasgow, Scotland.
44. Hulley S, Grady D, Bush T, et al for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
FREE FULL TEXT
45. LaRosa JC. Cholesterol management in women and the elderly. J Intern Med. 1997;157:961-968.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Statins and Risk of Coronary Heart Disease
Neal D. Clemenson, Shah Ebrahim, George Davey Smith, and John C. LaRosa
JAMA. 2000;283(22):2935.
EXTRACT
| FULL TEXT
RELATED ARTICLE
December 22/29, 1999
JAMA. 1999;282(24):2419-2420.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Potential survival gains in the treatment of myocardial infarction
Chew et al.
Heart 2009;95:1844-1850.
ABSTRACT
| FULL TEXT
Defining knowledge translation
Straus et al.
CMAJ 2009;181:165-168.
FULL TEXT
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia
Tremblay et al.
J. Lipid Res. 2009;50:1463-1471.
ABSTRACT
| FULL TEXT
Impact of a Multifaceted Intervention on Cholesterol Management in Primary Care Practices: Guideline Adherence for Heart Health Randomized Trial
Bertoni et al.
Arch Intern Med 2009;169:678-686.
ABSTRACT
| FULL TEXT
The LDL Receptor
Goldstein and Brown
Arterioscler. Thromb. Vasc. Bio. 2009;29:431-438.
ABSTRACT
| FULL TEXT
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Pletcher et al.
ANN INTERN MED 2009;150:243-254.
ABSTRACT
| FULL TEXT
The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines
Mora et al.
Clin. Chem. 2009;55:219-228.
ABSTRACT
| FULL TEXT
ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine
Krumholz et al.
J Am Coll Cardiol 2008;52:2046-2099.
FULL TEXT
ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction): Developed in Collaboration With the American Academy of Family Physicians and the American College of Emergency Physicians: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine
WRITING COMMITTEE MEMBERS et al.
Circulation 2008;118:2596-2648.
FULL TEXT
Interaction between statins and clopidogrel: is there anything clinically relevant?
Bhindi et al.
QJM 2008;101:915-925.
ABSTRACT
| FULL TEXT
Primary Prevention and Statins: Is It Just About Going to Class?
Krasuski
Mayo Clin Proc. 2008;83:1313-1315.
FULL TEXT
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Postgrad. Med. J. 2008;84:590-598.
ABSTRACT
| FULL TEXT
Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction
Austin et al.
CMAJ 2008;179:895-900.
ABSTRACT
| FULL TEXT
Lovastatin Inhibits TGF-{beta}-Induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts
Meyer-ter-Vehn et al.
IOVS 2008;49:3955-3960.
ABSTRACT
| FULL TEXT
Assessing Multiple Medication Use With Probabilities of Benefits and Harms
Murphy et al.
J Aging Health 2008;20:694-709.
ABSTRACT
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Heart 2008;94:706-714.
ABSTRACT
| FULL TEXT
Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study
Wenger et al.
Heart 2008;94:434-439.
ABSTRACT
| FULL TEXT
Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment
Krauss et al.
Circulation 2008;117:1537-1544.
ABSTRACT
| FULL TEXT
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial.
Miller et al.
J Am Coll Cardiol 2008;51:724-730.
ABSTRACT
| FULL TEXT
Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT
Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
Afilalo et al.
J Am Coll Cardiol 2008;51:37-45.
ABSTRACT
| FULL TEXT
EP2306 [2-(4-Biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], A Novel Squalene Synthase Inhibitor, Reduces Atherosclerosis in the Cholesterol-Fed Rabbit
Tavridou et al.
J. Pharmacol. Exp. Ther. 2007;323:794-804.
ABSTRACT
| FULL TEXT
Atorvastatin Treatment and Vaccination Efficacy
Packard et al.
J Clin Pharmacol 2007;47:1022-1027.
FULL TEXT
The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT
| FULL TEXT
Squalene Synthase, a Determinant of Raft-associated Cholesterol and Modulator of Cancer Cell Proliferation
Brusselmans et al.
J. Biol. Chem. 2007;282:18777-18785.
ABSTRACT
| FULL TEXT
Risk assessment in diabetes management: how do general practitioners estimate risks due to diabetes?
Haussler et al.
Qual Saf Health Care 2007;16:208-212.
ABSTRACT
| FULL TEXT
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein et al.
NEJM 2007;356:1620-1630.
ABSTRACT
| FULL TEXT
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel et al.
Eur Heart J 2007;28:664-672.
ABSTRACT
| FULL TEXT
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley et al.
NEJM 2007;356:775-789.
ABSTRACT
| FULL TEXT
Effects of Past and Recent Blood Pressure and Cholesterol Level on Coronary Heart Disease and Stroke Mortality, Accounting for Measurement Error
Boshuizen et al.
Am J Epidemiol 2007;165:398-409.
ABSTRACT
| FULL TEXT
Statin Therapy and the Elderly: SAGE Advice?
Gotto
Circulation 2007;115:681-683.
FULL TEXT
Aspirin for the Primary Prevention of Cardiovascular Disease in Women: A Cost-Utility Analysis
Pignone et al.
Arch Intern Med 2007;167:290-295.
ABSTRACT
| FULL TEXT
Sex differences in the effectiveness of statins after myocardial infarction
Karp et al.
CMAJ 2007;176:333-338.
ABSTRACT
| FULL TEXT
Relationship Between Adherence to Evidence-Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction
Rasmussen et al.
JAMA 2007;297:177-186.
ABSTRACT
| FULL TEXT
Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study
Penning-van Beest et al.
Eur Heart J 2007;28:154-159.
ABSTRACT
| FULL TEXT
Primary Prevention of Cardiovascular Diseases With Statin Therapy: A Meta-analysis of Randomized Controlled Trials
Thavendiranathan et al.
Arch Intern Med 2006;166:2307-2313.
ABSTRACT
| FULL TEXT
Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?
Milani and Lavie
J Am Coll Cardiol 2006;48:1791-1792.
FULL TEXT
Statin therapy and risks for death and hospitalization in chronic heart failure.
Go et al.
JAMA 2006;296:2105-2111.
ABSTRACT
| FULL TEXT
Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis?
van Leuven et al.
Lupus 2006;15:11-17.
ABSTRACT
Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention.
Franco et al.
J. Epidemiol. Community Health 2006;60:839-845.
ABSTRACT
| FULL TEXT
The gap between theory and practice: what do the trials tell us?
Pedersen
Eur Heart J Suppl 2006;8:F10-F16.
ABSTRACT
| FULL TEXT
Epidemiology of low HDL-cholesterol: results of studies and surveys
Bruckert
Eur Heart J Suppl 2006;8:F17-F22.
ABSTRACT
| FULL TEXT
Niaspan(R) in the management of dyslipidaemia: the evidence
Brown
Eur Heart J Suppl 2006;8:F60-F67.
ABSTRACT
| FULL TEXT
Simvastatin-Induced Decline in Cognition
Padala et al.
The Annals of Pharmacotherapy 2006;40:1880-1883.
ABSTRACT
| FULL TEXT
Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment
Pedersen et al.
Diabetes and Vascular Disease Research 2006;3:S1-S12.
ABSTRACT
Potential therapeutic role for statins in respiratory disease.
Hothersall et al.
Thorax 2006;61:729-734.
ABSTRACT
| FULL TEXT
A 39-year-old woman with hypercholesterolemia.
Mittleman
JAMA 2006;296:319-326.
ABSTRACT
| FULL TEXT
Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study
Manuel et al.
BMJ 2006;332:1419.
ABSTRACT
| FULL TEXT
Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease.
Paul-Labrador et al.
Arch Intern Med 2006;166:1218-1224.
ABSTRACT
| FULL TEXT
The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina
Daly et al.
Eur Heart J 2006;27:1298-1304.
ABSTRACT
| FULL TEXT
Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk
El Fakiri et al.
Heart 2006;92:741-745.
ABSTRACT
| FULL TEXT
Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology
Stramba-Badiale et al.
Eur Heart J 2006;27:994-1005.
ABSTRACT
| FULL TEXT
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone et al.
ANN INTERN MED 2006;144:326-336.
ABSTRACT
| FULL TEXT
The polypill: at what price would it become cost effective?
Franco et al.
J. Epidemiol. Community Health 2006;60:213-217.
ABSTRACT
| FULL TEXT
Apparent and Internal Validity of a Monte Carlo-Markov Model for Cardiovascular Disease in a Cohort Follow-up Study
Nijhuis et al.
Med Decis Making 2006;26:134-144.
ABSTRACT
Statin Treatment and Diabetes Affect Myeloperoxidase Activity in Maintenance Hemodialysis Patients
Stenvinkel et al.
CJASN 2006;1:281-287.
ABSTRACT
| FULL TEXT
Inflammation and cardiovascular disease mechanisms
Libby
Am. J. Clin. Nutr. 2006;83:456S-460S.
ABSTRACT
| FULL TEXT
Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?
van Leuven et al.
Cardiovasc Res 2006;69:341-347.
ABSTRACT
| FULL TEXT
Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and Statins
Urso et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:2560-2566.
ABSTRACT
| FULL TEXT
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared by: British Cardiac Society, British Hype
Heart 2005;91:v1-v52.
FULL TEXT
Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia
Despres et al.
NEJM 2005;353:2121-2134.
ABSTRACT
| FULL TEXT
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
Robinson et al.
J Am Coll Cardiol 2005;46:1855-1862.
ABSTRACT
| FULL TEXT
Cost effectiveness of statins in coronary heart disease
Franco et al.
J. Epidemiol. Community Health 2005;59:927-933.
ABSTRACT
| FULL TEXT
Perspectives on Dyslipidemia and Coronary Heart Disease in Women
Bittner
J Am Coll Cardiol 2005;46:1628-1635.
ABSTRACT
| FULL TEXT
Trends in Serum Lipids and Lipoproteins of Adults, 1960-2002
Carroll et al.
JAMA 2005;294:1773-1781.
ABSTRACT
| FULL TEXT
Effect Size Estimates of Lifestyle and Dietary Changes on All-Cause Mortality in Coronary Artery Disease Patients: A Systematic Review
Iestra et al.
Circulation 2005;112:924-934.
ABSTRACT
| FULL TEXT
Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome: A Novel Marker for Early Diagnosis
Hayashida et al.
Circulation 2005;112:812-818.
ABSTRACT
| FULL TEXT
The realities of dyslipidaemia: what do the studies tell us?
Kastelein
Eur Heart J Suppl 2005;7:F27-F33.
ABSTRACT
| FULL TEXT
Commentary
Levy and Pearson
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2005;60:597-598.
FULL TEXT
Potential Adverse Effects of Statins on Muscle
Tomlinson and Mangione
ptjournal 2005;85:459-465.
FULL TEXT
The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed
Manuel et al.
CMAJ 2005;172:1027-1031.
FULL TEXT
The analysis by Manuel and colleagues creates controversy with headlines, not data
Genest et al.
CMAJ 2005;172:1033-1034.
FULL TEXT
Effect of Intensive Lipid Lowering, With or Without Antioxidant Vitamins, Compared With Moderate Lipid Lowering on Myocardial Ischemia in Patients With Stable Coronary Artery Disease: The Vascular Basis for the Treatment of Myocardial Ischemia Study
Stone et al.
Circulation 2005;111:1747-1755.
ABSTRACT
| FULL TEXT
Simvastatin over the counter
DTB 2005;43:25-28.
ABSTRACT
| FULL TEXT
Statins and Blood Coagulation
Undas et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:287-294.
ABSTRACT
| FULL TEXT
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT
| FULL TEXT
Raising HDL-C and lowering triglycerides: benefits beyond LDL-C modification
Shepherd
British Journal of Diabetes & Vascular Disease 2005;5:S12-S16.
ABSTRACT
Modern intervention strategies for managing dyslipidaemia: the case for combination therapy
Drexel
British Journal of Diabetes & Vascular Disease 2005;5:S17-S23.
ABSTRACT
Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia
Meagher
J Am Board Fam Med 2004;17:424-437.
ABSTRACT
| FULL TEXT
CRP and Risk of Coronary Heart Disease: Can Exercise Training Cool Down the Flames?
Despres
Arterioscler. Thromb. Vasc. Bio. 2004;24:1743-1745.
FULL TEXT
Long term persistence with statin treatment in daily medical practice
Mantel-Teeuwisse et al.
Heart 2004;90:1065-1066.
FULL TEXT
Impact of Angiotensin-Converting Enzyme Inhibitors and Statins on Survival in Idiopathic Pulmonary Fibrosis
Nadrous et al.
Chest 2004;126:438-446.
ABSTRACT
| FULL TEXT
Management of dyslipidaemia
Thompson
Heart 2004;90:949-955.
FULL TEXT
Serum Total and Lipoprotein Cholesterol Levels and Awareness, Treatment, and Control of Hypercholesterolemia in China
He et al.
Circulation 2004;110:405-411.
ABSTRACT
| FULL TEXT
Foreword
LaRosa and Pedersen
Eur Heart J Suppl 2004;6:C1-C4.
FULL TEXT
Observational Studies of Treatment Effectiveness: Some Cautions
Laupacis and Mamdani
ANN INTERN MED 2004;140:923-924.
FULL TEXT
Commentary: Observation versus intervention--what's different?
Barrett-Connor
Int J Epidemiol 2004;33:457-459.
FULL TEXT
Drug Treatment of Hyperlipidemia in Women
Walsh and Pignone
JAMA 2004;291:2243-2252.
ABSTRACT
| FULL TEXT
Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox
Ko et al.
JAMA 2004;291:1864-1870.
ABSTRACT
| FULL TEXT
Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction
Dalal et al.
BMJ 2004;328:693-697.
FULL TEXT
|
